<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00771433</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000599535</org_study_id>
    <secondary_id>FRE-CFB-LENO-SEIN</secondary_id>
    <secondary_id>INCA-RECF0516</secondary_id>
    <secondary_id>EUDRACT-2007-002753-23</secondary_id>
    <secondary_id>FRE-CFB-CFB/2007-01</secondary_id>
    <secondary_id>CHUGAI-FRE-CFB-LENO-SEIN</secondary_id>
    <nct_id>NCT00771433</nct_id>
  </id_info>
  <brief_title>G-CSF in Preventing Neutropenia in Women Receiving Chemotherapy for Breast Cancer</brief_title>
  <official_title>Evaluation of the Efficacy of Adding Daily G-CSF (Granulocyte Colony Stimulating Factor) for Prevention of Hematologic Toxicity Due to Neoadjuvant or Adjvuant Chemotherapy in Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Francois Baclesse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: G-CSF may prevent or reduce febrile neutropenia in women receiving chemotherapy&#xD;
      for breast cancer. It is not yet known which G-CSF regimen is more effective in preventing&#xD;
      neutropenia.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well G-CSF works in preventing neutropenia in&#xD;
      women receiving chemotherapy for breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Evaluate the efficacy of filgrastim (G-CSF) in preventing hematological toxicity in&#xD;
           women with breast cancer receiving neoadjuvant or adjuvant chemotherapy.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Compare actual vs theoretical dose intensity.&#xD;
&#xD;
      OUTLINE: This is a multicenter study. Patients are stratified according to age (&lt; 65 years vs&#xD;
      â‰¥ 65 years) and prior chemotherapy (adjuvant vs neoadjuvant). Patients are assigned to 1 of 2&#xD;
      groups.&#xD;
&#xD;
        -  Group 1: Patients receive filgrastim (G-CSF) subcutaneously (SC) once daily on days 6-11&#xD;
           of each course of chemotherapy as primary prophylaxis. Chemotherapy courses repeat every&#xD;
           three weeks for 3-6 courses.&#xD;
&#xD;
        -  Group 2: Patients receive G-CSF SC once daily on days 6-11 of each course of&#xD;
           chemotherapy as primary prophylaxis. Chemotherapy courses repeat every three weeks for&#xD;
           3-6 courses. Patients may also receive secondary prophylaxis with G-CSF if they&#xD;
           experience an episode of neutropenia.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <primary_purpose>Supportive Care</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of febrile neutropenia</measure>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Chemotherapeutic Agent Toxicity</condition>
  <condition>Neutropenia</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive filgrastim (G-CSF) subcutaneously (SC) once daily on days 6-11 of each course of chemotherapy as primary prophylaxis. Chemotherapy courses repeat every three weeks for 3-6 courses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive G-CSF SC once daily on days 6-11 of each course of chemotherapy as primary prophylaxis. Chemotherapy courses repeat every three weeks for 3-6 courses. Patients may also receive secondary prophylaxis with G-CSF if they experience an episode of neutropenia.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
    <description>Given subcutaneously</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of breast cancer&#xD;
&#xD;
          -  Receiving 1 of the following neoadjuvant or adjuvant chemotherapy regimens:&#xD;
&#xD;
               -  Six courses of epirubicin hydrochloride and docetaxel&#xD;
&#xD;
               -  Six courses of fluorouracil, epirubicin hydrochloride, and cyclophosphamide (FEC)&#xD;
                  100 or 3 courses of FEC 100 and 3 courses of docetaxel 100&#xD;
&#xD;
          -  Must have received at least 2 chemotherapy regimens prior to study therapy&#xD;
&#xD;
          -  No malignant hematological disease&#xD;
&#xD;
          -  Hormone receptor status not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Menopausal status not specified&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No contraindications to standard neoadjuvant or adjuvant chemotherapy&#xD;
&#xD;
          -  No known hypersensitivity to G-CSF or any of its components&#xD;
&#xD;
          -  No patients deprived of liberty or under guardianship&#xD;
&#xD;
          -  No psychological, familial, social, or geographical reasons preventing follow-up&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No concurrent participation in another experimental drug study&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Corinne Delcambre</last_name>
    <role>Study Chair</role>
    <affiliation>Centre Francois Baclesse</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Regional Francois Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2008</verification_date>
  <study_first_submitted>October 10, 2008</study_first_submitted>
  <study_first_submitted_qc>October 10, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 13, 2008</study_first_posted>
  <last_update_submitted>May 12, 2011</last_update_submitted>
  <last_update_submitted_qc>May 12, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 13, 2011</last_update_posted>
  <keyword>neutropenia</keyword>
  <keyword>chemotherapeutic agent toxicity</keyword>
  <keyword>recurrent breast cancer</keyword>
  <keyword>stage I breast cancer</keyword>
  <keyword>stage II breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>stage IIIB breast cancer</keyword>
  <keyword>stage IIIC breast cancer</keyword>
  <keyword>stage IV breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Neutropenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

